Skip to content

News

(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report. Status and OutlookSince completing...
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...
(Stockholm, 27 February 2024) Asarina Pharma (“the Company”) today releases its Second Half-Year and Year-End Report for 2023. The full Report...
Asarina Pharma AB today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB. The Company has entered into an...
Stockholm, 16 November 2023. Asarina Pharma AB (publ., “Asarina” or “the Company”) today provides an update on its partnering activities...
(Stockholm, 23 August 2023) Asarina Pharma today releases its First Half-Year Report for 2023. In addition to the financial statements for H1/2023, the...
Consultant Neurologist Dr. Heidi Biernat, Head of the Tourette Clinic at Copenhagen’s Bispebjerg University Hospital and Principal Investigator in...
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on...
The Phase IIa results demonstrated that Sepranolone could become the first-line pharma treatment for Tourette as it showed competitive tic reduction and...